X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Growth in innovative, value-based contracts holds promise for the health system and for patients

By Katie Koziara  |    September 24, 2020
The extraordinary financial pressure COVID-19 is creating for the U.S. economy underscores the need for a renewed push toward a more value-driven health care system that prioritizes patient access...   Read More

Innovative contracts drive access for patients and value for the system

By Katie Koziara  |    September 9, 2020
Our health care system is far from perfect, but there are solutions that will help address patient affordability concerns without sacrificing innovation, access or quality of care. For example,...   Read More

ICYMI: Patients saved nearly $800,000 out of pocket through innovative contracting arrangements

By Katie Koziara  |    April 20, 2020
Value-based programs between biopharmaceutical companies and pharmacy benefit manager Express Scripts saved $4.3 billion on medicines last year. Patients in these plans with innovative contracting...   Read More

Low-value health care costs $345B each year and provides little benefit

By Katie Koziara  |    February 26, 2020
Low-value health care is treatment that offers little to no clinical benefit to patients yet is a major drain of resources often at the detriment to patients. Low-value health care is one of the...   Read More

Addressing barriers that inhibit value-based contracts

By Katie Koziara  |    February 21, 2020
With 56 new medicines approved by the U.S. Food and Drug Administration (FDA) in 2019 and over 8,000 medicines in development around the globe, innovative medicines are transforming the way we...   Read More

Guest post: Value-based agreements can improve outcomes and even save patients money at the pharmacy counter

By Guest Contributor  |    November 7, 2019
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

New data show how ICER’s value framework could prevent or delay access to treatments for Medicaid patients across the country

By Katie Koziara  |    November 4, 2019
A new analysis from Xcenda applied the Institute for Clinical and Economic Review’s (ICER) value assessments to state Medicaid programs in California, Massachusetts, Maryland, Nevada and New York....   Read More

5 Ways to improve ICER’s value assessment framework

By Lauren Neves  |    June 20, 2019
The Institute for Clinical and Economic Review’s (ICER) recently made a call for suggestions and feedback on how to improve its value assessment framework and methods. We are a strong supporter of...   Read More

Assessing value top of mind at ISPOR 2019

By Samantha Dougherty  |    June 5, 2019
As we move toward a value-driven health care system, the focus should be on outcomes that matter most to patients, such as how medicines make patients feel, whether they can return to work or how...   Read More

New analysis shows 820,000 prescriptions would be in jeopardy if ICER’s value framework is used in Medicaid

By Katie Koziara  |    March 20, 2019
A new analysis from Xcenda found that if Medicaid were to use one-size-fits-all value assessments like the Institute for Clinical and Economic Review’s (ICER) framework as the basis for accessing...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Date

see all

Subscribe to Email Updates